Over the last year, biosimilars have seen increasing success in the US market. The number of biosimilars approved has accelerated, product sales for biosimilars are increasing, net prices are being driven down (for both brands and biosimilars), and payers are beginning to prefer biosimilars over brands on their formularies.

In this white paper, we take a closer look at these trends, providing an in-depth analysis of the US market. To download the paper, fill out the form below:

Download the white paper